On air · 2 of 3 networks
MedShr
- medshr.it
- GB
- 74 employees
MedShr’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 2,990. Watch MedShr with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 1,597 | Checked 29 Oct 2026 | See all 2,990 ads → | ||
| Meta | Running | 7 | Active ads on the Meta Ad Library, all countries | Checked 30 Oct 2026 | Collect them with the API → |
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 4 Oct 2026 | Collect them with the API → |
MedShr has 1,597 live LinkedIn ads. Its Facebook page had 7 active ads on 30 Oct 2026, and we recorded no Google ads on 4 Oct 2026.
Latest ads
- LINKEDIN · IMAGESince 16 Oct 2026
Immunotherapy is reshaping treatment expectations in dMMR/MSI-H colorectal cancer, from metastatic disease to earlier-stage treatment strategies. This free educational content is supported by GSK and intended for healthcare professionals. To access this and other medical education on MedShr, sign up for free using your workplace ID or medical credentials.
- LINKEDIN · IMAGESince 16 Oct 2026
A right-sided metastatic CRC with MLH1/PMS2 loss raises a key question: which molecular findings help determine the likely underlying pathway? This free educational content is supported by GSK and intended for healthcare professionals. To access this and other medical education on MedShr, sign up for free using your workplace ID or medical credentials.
- LINKEDIN · IMAGESince 16 Oct 2026
A case-based discussion on balancing efficacy, immune-related toxicity, and multidisciplinary monitoring in dMMR/MSI-H colon cancer. This free educational content is supported by GSK and intended for healthcare professionals. To access this and other medical education on MedShr, sign up for free using your workplace ID or medical credentials.
- LINKEDIN · IMAGESince 16 Oct 2026
A practical review of immunotherapy evidence across metastatic, locally advanced rectal, and non-metastatic colon cancer settings. This free educational content is supported by GSK and intended for healthcare professionals. To access this and other medical education on MedShr, sign up for free using your workplace ID or medical credentials.
- LINKEDIN · IMAGESince 16 Oct 2026
Identifying dMMR/MSI status can influence Lynch syndrome assessment, prognosis, and treatment selection in patients with colorectal cancer. This free educational content is supported by GSK and intended for healthcare professionals. To access this and other medical education on MedShr, sign up for free using your workplace ID or medical credentials.
- LINKEDIN · IMAGESince 16 Oct 2026
Pre-existing autoimmune disease can complicate first-line decisions, but does not automatically rule out immunotherapy in dMMR/MSI-H colorectal cancer. This free educational content is supported by GSK and intended for healthcare professionals. To access this and other medical education on MedShr, sign up for free using your workplace ID or medical credentials.
6 of 2,990 adsSign up to see every MedShr ad, filter by format and date, and get alerts on new ones.
See all 2,990 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.